secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2021-10-18T23:59:59+00:00
Accession:  0001558370-21-013248
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Rajeev Shah resigns; C. Daniel Myers appointed to board
----------------------------------------------------------------

- Rajeev Shah resigned effective Oct 15, 2021; no disagreement with company on operations.
- C. Daniel Myers appointed as Class III director, term expiring at 2023 annual meeting.
- Myers is CEO of MediPrint Ophthalmics, former CEO and co-founder of Alimera Sciences.
- Myers received option to purchase 42,000 shares at $2.21, vesting over three years.
- Myers also appointed to Compensation Committee and Nominating and Corporate Governance Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837021013248/0001558370-21-013248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837021013248/kala-20211014x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-013248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer